@article{1841450359bc4180b513f74145c39bfa,
title = "Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment",
abstract = "BACKGROUND: The introduction of direct-acting antivirals (DAA) has increased sustained virological response (SVR) rates in patients with advanced liver disease and chronic hepatitis C(CHC)infection. At present, data on clinical outcome and long-term durability of viral eradication after successful DAA therapy are scarce.AIM: To evaluate the long-term success of viral eradication in patients with advanced fibrosis or cirrhosis treated with DAAs.METHODS: Five hundred and fifty-one patients with advanced fibrosis (n = 158) or cirrhosis (CPS-A:317,CPS-B/C:76) and SVR after interferon and ribavirin-free DAA therapy treated between October 2013 and April 2016 were studied with a median follow-up of 65.6 (13.0-155.3) weeks. Only patients without hepatocellular carcinoma (HCC) at baseline and without liver transplantation were included.RESULTS: Twelve patients (2.2%) died during follow-up: the mortality rate was 0.6% in F3, 2.2% in CPS-A and 5.3% in CPS-B/C patients (P = .08). During follow-up 36 patients with cirrhosis (9.1%) developed a liver related event, including 16 with de-novo HCC (4.1%). Seven patients were transplanted at a median of 9.7 (range 3.8-21.7) months after EOT. History of decompensation was significantly associated with liver related events during follow-up (HR 7.9; 95% CI 2.7-22.6; P < .001), and with mortality (HR 5.5; 95% CI 1.5-20.2, P = .01).CONCLUSIONS: Eradication of HCV by DAA therapy was durable irrespective of the DAA combination used. Most of the cured patients had an excellent long-term clinical prognosis. Nevertheless, the risk of new occurrence of HCC remains worrisome and thus regular surveillance is obligatory even after clinical stabilization and improvement of the patient.",
keywords = "Aged, Antiviral Agents/therapeutic use, Austria, Carcinoma, Hepatocellular/complications, Female, Follow-Up Studies, Hepatitis C, Chronic/complications, Humans, Interferons, Liver Cirrhosis/complications, Liver Neoplasms/complications, Logistic Models, Male, Middle Aged, Ribavirin, Sustained Virologic Response, interferon-free treatment, follow-up, sustained virological response, cirrhosis",
author = "Karin Kozbial and Stephan Moser and Ramona Al-Zoairy and Remy Schwarzer and Christian Datz and Rudolf Stauber and Hermann Laferl and Michael Strasser and Sandra Beinhardt and St{\"a}ttermayer, {Albert F} and Michael Gschwantler and Heinz Zoller and Andreas Maieron and Ivo Graziadei and Michael Trauner and Petra Steindl-Munda and Harald Hofer and Peter Ferenci",
note = "Funding Information: Karin Kozbial: Travel support from Gilead, BMS, AbbVie; Stephan Moser: Travel support from Gilead, BMS, AbbVie and speakers{\textquoteright} honorarium from BMS; Ramona Al-Zoairy: Speakers{\textquoteright} honorarium and travel support from AbbVie; Remy Schwarzer: Nothing to declare; Christian Datz: Advisor and speaker for Gilead, MSD, BMS and AbbVie; grants from Gilead, AbbVie and MSD. Rudolf Stauber: Member of advisory board: AbbVie, BMS, Gilead, MSD; speaker honoraria from AbbVie, BMS, Gilead; unrestricted research grants from: AbbVie, MSD. Hermann Laferl: Travel support from Roche, Gilead and AbbVie; member of advisory board: Janssen, AbbVie, MSD. Michael Strasser: Advisor/speaker for MSD, Gilead and AbbVie, grants from Gilead, AbbVie and MSD. Sandra Beinhardt: Speakers{\textquoteright} honoraria from BMS; member of advisory board: AbbVie; travel support from: Roche, Janssen, Gilead, AbbVie; Albert Friedrich St{\"a}ttermayer: Travel support from Roche, Janssen, Gilead. Michael Gschwantler: Advisor and speaker for Janssen, MSD, BMS, Gilead, and AbbVie, grants from Gilead, AbbVie and MSD. Heinz Zoller: Member of the Gilead Speakers{\textquoteright} Bureau; honoraria for lecturing from AbbVie, BMS, Gilead and MSD. Andreas Maieron: Advisor and speaker for Janssen, MSD, BMS, Gilead, and AbbVie, grants from Gilead, AbbVie and MSD. Ivo Graziadei: Member of advisory board: AbbVie, MSD, BMS, Gilead; speakerE꤀s honoraria: BMS, Gilead, AbbVie, MSD. Michael Trauner: Consultant for Albireo, Falk, Genfit, Gilead, Intercept, MSD, Novartis and Phenex; member of the speakers{\textquoteright} bureau of Falk, Gilead, and MSD; travel grants from Falk and Gilead; unrestricted research grants from Albireo, Falk, Gilead, Intercept, MSD and Takeda. He is also co-inventor of a patent on the medical use of norUDCA. Petra Steindl-Munda: Advisory board and speakers{\textquoteright} honoraria from Gilead, AbbVie, Janssen, MSD, BMS; travel grants from AbbVie, Gilead and Falk. Harald Hofer: lecture fees from AbbVie, MSD, BMS, Gilead, and Janssen; advisory board member of: AbbVie, MSD, BMS, Gilead, and Janssen. Unrestricted research grant from AbbVie. Peter Ferenci: member of the global advisory board Gilead, MSD, BMS, and Abbvie; unrestricted research grant from Gilead Austria. Publisher Copyright: {\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd",
year = "2018",
month = jun,
doi = "10.1111/liv.13629",
language = "English",
volume = "38",
pages = "1028--1035",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "6",
}